Wiley Online Library has indexed a peer-reviewed review titled "A review of skin microbiome and new challenges to cosmetic microbiome-friendly formulations," a stocktake of the science behind one of personal care's fastest-evolving claim categories.

The review arrives at a moment when "microbiome-friendly" has moved from a niche descriptor on indie labels to a mainstream expectation. Several of the largest personal-care companies have built multi-product ranges around prebiotic, postbiotic and probiotic positioning. The Wiley paper's title alone — with its explicit reference to "new challenges" — signals that early formulation assumptions need revisiting.

What is the review asking?

The title points to two simultaneous conversations: a scientific one about how cutaneous microbial communities actually function, and an industrial one about what "microbiome-friendly" requires of a finished formula. The review frames the skin microbiome as a structured ecosystem shaped by sebum composition, pH, hydration, and the resident populations of Cutibacterium, Staphylococcus, Corynebacterium and Malassezia species — not as a marketing abstraction.

Industry context makes the question urgent. Most early microbiome-positioned launches relied on indirect substantiation: references to published prebiotic literature, in-vitro pathogen-suppression assays, or general "supports skin barrier" copy. National authorities — particularly within the EU's Cosmetic Products Regulation (EC) No 1223/2009 framework — now push brand owners to substantiate every benefit claim with documented evidence.

What challenges do formulators now face?

Four pressure points dominate the new formulation brief:

• Preservative selection. Broad-spectrum preservatives such as parabens, methylisothiazolinone (MIT) and formaldehyde releasers can suppress commensal populations alongside pathogens. The review's framing pushes formulators toward narrow-spectrum options: phenoxyethanol/ethylhexylglycerin systems, organic-acid blends (benzoic, sorbic, levulinic, anisic acids), or fermentation-derived antimicrobials.
• Surfactant systems. High-foam sulfate surfactants and aggressive anionic blends destabilize microbial diversity within hours of skin contact. Mild surfactants — decyl glucoside, coco-glucoside, sodium cocoyl isethionate — are increasingly specified for microbiome-claim briefs.
• Active-substrate design. Prebiotic substrates (inulin, alpha-glucan oligosaccharide, galacto-oligosaccharides, beta-glucan) and postbiotic lysates (heat-treated Lactobacillus, Bifida, Saccharomyces filtrates) require stability testing under new pH and water-activity constraints.
• Substantiation workload. ISO/AWI 24417, currently in development, aims to standardize skin microbiome analysis. Until publication, brands rely on 16S rRNA gene sequencing and shotgun metagenomics from contracted labs to document alpha- and beta-diversity outcomes in panelist swabs.

What does this change for brand owners?

Procurement officers will see the shift in the INCI list. Microbiome-positioned SKUs are increasingly built around shorter, milder surfactant decks and narrower preservative windows — at the cost of longer stability protocols and higher microbial-challenge testing spend. R&D leads at major and indie brands now face a substantiation workload that mirrors the one clinical skincare absorbed a decade earlier.

Treatment-menu operators in esthetics clinics and dermatology offices can expect branded microbiome services to move from ritual language toward quantitative readouts. The next twelve months will likely show whether sequencing-based "microbiome analysis" services translate into repeat bookings or fade as a novelty add-on.

What to watch next

Three data points will shape the next year:

• The publication timeline for ISO 24417, which would create the first analytical standard for skin microbiome testing.
• Regulatory challenge volume inside the EU under (EC) No 1223/2009 for non-substantiated microbiome claims.
• Whether major brands move from 16S panels to full shotgun metagenomics for claim substantiation, a shift that would compress lab pricing across the testing-services market.

Until then, the Wiley review gives formulators and compliance leads a shared reference point: the "microbiome-friendly" label now carries an evidentiary burden comparable to clinical skincare claims.